Liquidia to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Liquidia Technologies (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company, announced that CEO Neal Fowler will present an overview at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 10:30 AM ET. The event will be accessible via a live audio webcast, available on the company’s website and archived for 90 days. Liquidia focuses on developing novel products using its proprietary PRINT® technology, aiming to enhance therapy safety and efficacy. Notable product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain.

News Market Reaction – LQDA

+4.64%

+4.64% Session move

In the trading session that priced this news, LQDA gained 4.64%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT^® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:30am Eastern time.

A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT^® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investor Relations:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

 

FAQ

What will Liquidia Technologies present at the Jefferies Virtual Healthcare Conference?

Liquidia Technologies will have CEO Neal Fowler present a company overview at the Jefferies Virtual Healthcare Conference.

When is Liquidia's presentation scheduled at the Jefferies Virtual Healthcare Conference?

The presentation is scheduled for June 2, 2020, at 10:30 AM Eastern time.

Where can I find the live audio webcast of Liquidia's conference presentation?

The live audio webcast will be available on Liquidia's Events & Presentations page on their corporate website.

What is Liquidia Technologies focusing on with its PRINT technology?

Liquidia focuses on developing and commercializing novel biopharmaceutical products using its PRINT technology to improve the safety and efficacy of therapies.

What are the key product candidates of Liquidia Technologies?

Liquidia is developing LIQ861 for pulmonary arterial hypertension and LIQ865 for local post-operative pain.